Minimal Residual Disease Testing Market Size & Share Analysis - Trends, Drivers, Competitive Landscape, and Forecasts (2024 - 2030)

Chapter 1. Research Scope

1.1. Research Objectives

1.2. Market Definition

1.3. Analysis Period

1.4. Market Size Breakdown by Segment

1.4.1. Market size breakdown, by test type

1.4.2. Market size breakdown, by application

1.4.3. Market size breakdown, by technology

1.4.4. Market size breakdown, by end user

1.4.5. Market size breakdown, by region

1.4.6. Market size breakdown, by country

1.5. Market Data Reporting Unit

1.5.1. Value

1.6. Key Stakeholders

Chapter 2. Research Methodology

2.1. Secondary Research

2.1.1. Paid

2.1.2. Unpaid

2.1.3. P&S Intelligence database

2.2. Primary Research

2.3. Market Size Estimation

2.4. Data Triangulation

2.5. Currency Conversion Rates

2.6. Assumptions for the Study

2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Voice of Industry Experts/KOLs

Chapter 5. Market Indicators

Chapter 6. Industry Outlook

6.1. Market Dynamics

6.1.1. Trends

6.1.2. Drivers

6.1.3. Restraints/challenges

6.1.4. Impact analysis of drivers/restraints

6.2. Impact of COVID-19

6.3. Porter’s Five Forces Analysis

6.3.1. Bargaining power of buyers

6.3.2. Bargaining power of suppliers

6.3.3. Threat of new entrants

6.3.4. Intensity of rivalry

6.3.5. Threat of substitutes

Chapter 7. Global Market

7.1. Overview

7.2. Market Revenue, by Test Type (2019–2030)

7.3. Market Revenue, by Application (2019–2030)

7.3.1. Hematological malignancies testing market revenue, by type (2019–2030)

7.4. Market Revenue, by Technology (2019–2030)

7.5. Market Revenue, by End User (2019–2030)

7.6. Market Revenue, by Region (2019–2030)

Chapter 8. North America Market

8.1. Overview

8.2. Market Revenue, by Test Type (2019–2030)

8.3. Market Revenue, by Application (2019–2030)

8.3.1. Hematological malignancies testing market revenue, by type (2019–2030)

8.4. Market Revenue, by Technology (2019–2030)

8.5. Market Revenue, by End User (2019–2030)

8.6. Market Revenue, by Country (2019–2030)

Chapter 9. Europe Market

9.1. Overview

9.2. Market Revenue, by Test Type (2019–2030)

9.3. Market Revenue, by Application (2019–2030)

9.3.1. Hematological malignancies testing market revenue, by type (2019–2030)

9.4. Market Revenue, by Technology (2019–2030)

9.5. Market Revenue, by End User (2019–2030)

9.6. Market Revenue, by Country (2019–2030)

Chapter 10. APAC Market

10.1. Overview

10.2. Market Revenue, by Test Type (2019–2030)

10.3. Market Revenue, by Application (2019–2030)

10.3.1. Hematological malignancies testing market revenue, by type (2019–2030)

10.4. Market Revenue, by Technology (2019–2030)

10.5. Market Revenue, by End User (2019–2030)

10.6. Market Revenue, by Country (2019–2030)

Chapter 11. LATAM Market

11.1. Overview

11.2. Market Revenue, by Test Type (2019–2030)

11.3. Market Revenue, by Application (2019–2030)

11.3.1. Hematological malignancies testing market revenue, by type (2019–2030)

11.4. Market Revenue, by Technology (2019–2030)

11.5. Market Revenue, by End User (2019–2030)

11.6. Market Revenue, by Country (2019–2030)

Chapter 12. MEA Market

12.1. Overview

12.2. Market Revenue, by Test Type (2019–2030)

12.3. Market Revenue, by Application (2019–2030)

12.3.1. Hematological malignancies testing market revenue, by type (2019–2030)

12.4. Market Revenue, by Technology (2019–2030)

12.5. Market Revenue, by End User (2019–2030)

12.6. Market Revenue, by Country (2019–2030)

Chapter 13. U.S. Market

13.1. Overview

13.2. Market Revenue, by Test Type (2019–2030)

13.3. Market Revenue, by Application (2019–2030)

13.3.1. Hematological malignancies testing market revenue, by type (2019–2030)

13.4. Market Revenue, by Technology (2019–2030)

13.5. Market Revenue, by End User (2019–2030)

Chapter 14. Canada Market

14.1. Overview

14.2. Market Revenue, by Test Type (2019–2030)

14.3. Market Revenue, by Application (2019–2030)

14.3.1. Hematological malignancies testing market revenue, by type (2019–2030)

14.4. Market Revenue, by Technology (2019–2030)

14.5. Market Revenue, by End User (2019–2030)

Chapter 15. Germany Market

15.1. Overview

15.2. Market Revenue, by Test Type (2019–2030)

15.3. Market Revenue, by Application (2019–2030)

15.3.1. Hematological malignancies testing market revenue, by type (2019–2030)

15.4. Market Revenue, by Technology (2019–2030)

15.5. Market Revenue, by End User (2019–2030)

Chapter 16. France Market

16.1. Overview

16.2. Market Revenue, by Test Type (2019–2030)

16.3. Market Revenue, by Application (2019–2030)

16.3.1. Hematological malignancies testing market revenue, by type (2019–2030)

16.4. Market Revenue, by Technology (2019–2030)

16.5. Market Revenue, by End User (2019–2030)

Chapter 17. U.K. Market

17.1. Overview

17.2. Market Revenue, by Test Type (2019–2030)

17.3. Market Revenue, by Application (2019–2030)

17.3.1. Hematological malignancies testing market revenue, by type (2019–2030)

17.4. Market Revenue, by Technology (2019–2030)

17.5. Market Revenue, by End User (2019–2030)

Chapter 18. Italy Market

18.1. Overview

18.2. Market Revenue, by Test Type (2019–2030)

18.3. Market Revenue, by Application (2019–2030)

18.3.1. Hematological malignancies testing market revenue, by type (2019–2030)

18.4. Market Revenue, by Technology (2019–2030)

18.5. Market Revenue, by End User (2019–2030)

Chapter 19. Spain Market

19.1. Overview

19.2. Market Revenue, by Test Type (2019–2030)

19.3. Market Revenue, by Application (2019–2030)

19.3.1. Hematological malignancies testing market revenue, by type (2019–2030)

19.4. Market Revenue, by Technology (2019–2030)

19.5. Market Revenue, by End User (2019–2030)

Chapter 20. Japan Market

20.1. Overview

20.2. Market Revenue, by Test Type (2019–2030)

20.3. Market Revenue, by Application (2019–2030)

20.3.1. Hematological malignancies testing market revenue, by type (2019–2030)

20.4. Market Revenue, by Technology (2019–2030)

20.5. Market Revenue, by End User (2019–2030)

Chapter 21. China Market

21.1. Overview

21.2. Market Revenue, by Test Type (2019–2030)

21.3. Market Revenue, by Application (2019–2030)

21.3.1. Hematological malignancies testing market revenue, by type (2019–2030)

21.4. Market Revenue, by Technology (2019–2030)

21.5. Market Revenue, by End User (2019–2030)

Chapter 22. India Market

22.1. Overview

22.2. Market Revenue, by Test Type (2019–2030)

22.3. Market Revenue, by Application (2019–2030)

22.3.1. Hematological malignancies testing market revenue, by type (2019–2030)

22.4. Market Revenue, by Technology (2019–2030)

22.5. Market Revenue, by End User (2019–2030)

Chapter 23. Australia Market

23.1. Overview

23.2. Market Revenue, by Test Type (2019–2030)

23.3. Market Revenue, by Application (2019–2030)

23.3.1. Hematological malignancies testing market revenue, by type (2019–2030)

23.4. Market Revenue, by Technology (2019–2030)

23.5. Market Revenue, by End User (2019–2030)

Chapter 24. South Korea Market

24.1. Overview

24.2. Market Revenue, by Test Type (2019–2030)

24.3. Market Revenue, by Application (2019–2030)

24.3.1. Hematological malignancies testing market revenue, by type (2019–2030)

24.4. Market Revenue, by Technology (2019–2030)

24.5. Market Revenue, by End User (2019–2030)

Chapter 25. Brazil Market

25.1. Overview

25.2. Market Revenue, by Test Type (2019–2030)

25.3. Market Revenue, by Application (2019–2030)

25.3.1. Hematological malignancies testing market revenue, by type (2019–2030)

25.4. Market Revenue, by Technology (2019–2030)

25.5. Market Revenue, by End User (2019–2030)

Chapter 26. Mexico Market

26.1. Overview

26.2. Market Revenue, by Test Type (2019–2030)

26.3. Market Revenue, by Application (2019–2030)

26.3.1. Hematological malignancies testing market revenue, by type (2019–2030)

26.4. Market Revenue, by Technology (2019–2030)

26.5. Market Revenue, by End User (2019–2030)

Chapter 27. Saudi Arabia Market

27.1. Overview

27.2. Market Revenue, by Test Type (2019–2030)

27.3. Market Revenue, by Application (2019–2030)

27.3.1. Hematological malignancies testing market revenue, by type (2019–2030)

27.4. Market Revenue, by Technology (2019–2030)

27.5. Market Revenue, by End User (2019–2030)

Chapter 28. South Africa Market

28.1. Overview

28.2. Market Revenue, by Test Type (2019–2030)

28.3. Market Revenue, by Application (2019–2030)

28.3.1. Hematological malignancies testing market revenue, by type (2019–2030)

28.4. Market Revenue, by Technology (2019–2030)

28.5. Market Revenue, by End User (2019–2030)

Chapter 29. U.A.E. Market

29.1. Overview

29.2. Market Revenue, by Test Type (2019–2030)

29.3. Market Revenue, by Application (2019–2030)

29.3.1. Hematological malignancies testing market revenue, by type (2019–2030)

29.4. Market Revenue, by Technology (2019–2030)

29.5. Market Revenue, by End User (2019–2030)

Chapter 30. Competitive Landscape

30.1. List of Market Players and Their Offerings

30.2. Competitive Benchmarking of Key Players

30.3. Product Benchmarking of Key Players

30.4. Recent Strategic Developments

Chapter 31. Company Profiles

31.1. Adaptive Biotechnologies Corporation

31.1.1. Business overview

31.1.2. Product and service offerings

31.1.3. Key financial summary

31.2. F. Hoffmann-La Roche Ltd.

31.2.1. Business overview

31.2.2. Product and service offerings

31.2.3. Key financial summary

31.3. Cergentis B.V.

31.3.1. Business overview

31.3.2. Product and service offerings

31.4. Bio-Rad Laboratories Inc.

31.4.1. Business overview

31.4.2. Product and service offerings

31.4.3. Key financial summary

31.5. ARUP Laboratories

31.5.1. Business overview

31.5.2. Product and service offerings

31.5.3. Key financial summary

31.6. Laboratory Corporation of America Holdings

31.6.1. Business overview

31.6.2. Product and service offerings

31.6.3. Key financial summary

31.7. Guardant Health Inc.

31.7.1. Business overview

31.7.2. Product and service offerings

31.7.3. Key financial summary

31.8. Sysmex Corporation

31.8.1. Business overview

31.8.2. Product and service offerings

31.8.3. Key financial summary

31.9. Mission Bio Inc.

31.9.1. Business overview

31.9.2. Product and service offerings

31.10. Natera Inc.

31.10.1. Business overview

31.10.2. Product and service offerings

31.10.3. Key financial summary

31.11. NeoGenomics Laboratories Inc.

31.11.1. Business overview

31.11.2. Product and service offerings

31.11.3. Key financial summary

31.12. Exact Sciences Corporation

31.12.1. Business overview

31.12.2. Product and service offerings

31.12.3. Key financial summary

31.13. GRAIL LLC

31.13.1. Business overview

31.13.2. Product and service offerings

31.14. Veracyte Inc.

31.14.1. Business overview

31.14.2. Product and service offerings

31.14.3. Key financial summary

31.15. Foundation Medicine Inc.

31.15.1. Business overview

31.15.2. Product and service offerings

31.15.3. Key financial summary

Chapter 32. Appendix

32.1. Abbreviations

32.2. Sources and References

32.3. Related Reports

 

LIST OF TABLES

TABLE 1 ANALYSIS PERIOD OF THE STUDY

TABLE 2 DRIVERS FOR THE MARKET: IMPACT ANALYSIS

TABLE 3 RESTRAINTS FOR THE MARKET: IMPACT ANALYSIS

TABLE 4 GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2017–2022)

TABLE 5 GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2023–2026)

TABLE 6 GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2027–2030)

TABLE 7 GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2017–2022)

TABLE 8 GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2023–2026)

TABLE 9 GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2027–2030)

TABLE 10 GLOBAL HEMATOLOGICAL MALIGNANCIES TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 11 GLOBAL HEMATOLOGICAL MALIGNANCIES TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 12 GLOBAL HEMATOLOGICAL MALIGNANCIES TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 13 GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2017–2022)

TABLE 14 GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2023–2026)

TABLE 15 GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2027–2030)

TABLE 16 GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2017–2022)

TABLE 17 GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2023–2026)

TABLE 18 GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2027–2030)

TABLE 19 GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET, BY REGION, $M (2017–2022)

TABLE 20 GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET, BY REGION, $M (2023–2026)

TABLE 21 GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET, BY REGION, $M (2027–2030)

TABLE 22 NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2017–2022)

TABLE 23 NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2023–2026)

TABLE 24 NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2027–2030)

TABLE 25 NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2017–2022)

TABLE 26 NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2023–2026)

TABLE 27 NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2027–2030)

TABLE 28 NORTH AMERICA HEMATOLOGICAL MALIGNANCIES TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 29 NORTH AMERICA HEMATOLOGICAL MALIGNANCIES TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 30 NORTH AMERICA HEMATOLOGICAL MALIGNANCIES TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 31 NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2017–2022)

TABLE 32 NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2023–2026)

TABLE 33 NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2027–2030)

TABLE 34 NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2017–2022)

TABLE 35 NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2023–2026)

TABLE 36 NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2027–2030)

TABLE 37 NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY COUNTRY, $M (2017–2022)

TABLE 38 NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY COUNTRY, $M (2023–2026)

TABLE 39 NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY COUNTRY, $M (2027–2030)

TABLE 40 EUROPE MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2017–2022)

TABLE 41 EUROPE MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2023–2026)

TABLE 42 EUROPE MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2027–2030)

TABLE 43 EUROPE MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2017–2022)

TABLE 44 EUROPE MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2023–2026)

TABLE 45 EUROPE MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2027–2030)

TABLE 46 EUROPE HEMATOLOGICAL MALIGNANCIES TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 47 EUROPE HEMATOLOGICAL MALIGNANCIES TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 48 EUROPE HEMATOLOGICAL MALIGNANCIES TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 49 EUROPE MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2017–2022)

TABLE 50 EUROPE MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2023–2026)

TABLE 51 EUROPE MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2027–2030)

TABLE 52 EUROPE MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2017–2022)

TABLE 53 EUROPE MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2023–2026)

TABLE 54 EUROPE MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2027–2030)

TABLE 55 EUROPE MINIMAL RESIDUAL DISEASE TESTING MARKET, BY COUNTRY, $M (2017–2022)

TABLE 56 EUROPE MINIMAL RESIDUAL DISEASE TESTING MARKET, BY COUNTRY, $M (2023–2026)

TABLE 57 EUROPE MINIMAL RESIDUAL DISEASE TESTING MARKET, BY COUNTRY, $M (2027–2030)

TABLE 58 APAC MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2017–2022)

TABLE 59 APAC MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2023–2026)

TABLE 60 APAC MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2027–2030)

TABLE 61 APAC MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2017–2022)

TABLE 62 APAC MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2023–2026)

TABLE 63 APAC MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2027–2030)

TABLE 64 APAC HEMATOLOGICAL MALIGNANCIES TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 65 APAC HEMATOLOGICAL MALIGNANCIES TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 66 APAC HEMATOLOGICAL MALIGNANCIES TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 67 APAC MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2017–2022)

TABLE 68 APAC MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2023–2026)

TABLE 69 APAC MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2027–2030)

TABLE 70 APAC MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2017–2022)

TABLE 71 APAC MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2023–2026)

TABLE 72 APAC MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2027–2030)

TABLE 73 APAC MINIMAL RESIDUAL DISEASE TESTING MARKET, BY COUNTRY, $M (2017–2022)

TABLE 74 APAC MINIMAL RESIDUAL DISEASE TESTING MARKET, BY COUNTRY, $M (2023–2026)

TABLE 75 APAC MINIMAL RESIDUAL DISEASE TESTING MARKET, BY COUNTRY, $M (2027–2030)

TABLE 76 LATAM MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2017–2022)

TABLE 77 LATAM MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2023–2026)

TABLE 78 LATAM MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2027–2030)

TABLE 79 LATAM MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2017–2022)

TABLE 80 LATAM MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2023–2026)

TABLE 81 LATAM MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2027–2030)

TABLE 82 LATAM HEMATOLOGICAL MALIGNANCIES TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 83 LATAM HEMATOLOGICAL MALIGNANCIES TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 84 LATAM HEMATOLOGICAL MALIGNANCIES TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 85 LATAM MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2017–2022)

TABLE 86 LATAM MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2023–2026)

TABLE 87 LATAM MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2027–2030)

TABLE 88 LATAM MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2017–2022)

TABLE 89 LATAM MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2023–2026)

TABLE 90 LATAM MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2027–2030)

TABLE 91 LATAM MINIMAL RESIDUAL DISEASE TESTING MARKET, BY COUNTRY, $M (2017–2022)

TABLE 92 LATAM MINIMAL RESIDUAL DISEASE TESTING MARKET, BY COUNTRY, $M (2023–2026)

TABLE 93 LATAM MINIMAL RESIDUAL DISEASE TESTING MARKET, BY COUNTRY, $M (2027–2030)

TABLE 94 MEA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2017–2022)

TABLE 95 MEA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2023–2026)

TABLE 96 MEA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2027–2030)

TABLE 97 MEA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2017–2022)

TABLE 98 MEA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2023–2026)

TABLE 99 MEA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2027–2030)

TABLE 100 MEA HEMATOLOGICAL MALIGNANCIES TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 101 MEA HEMATOLOGICAL MALIGNANCIES TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 102 MEA HEMATOLOGICAL MALIGNANCIES TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 103 MEA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2017–2022)

TABLE 104 MEA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2023–2026)

TABLE 105 MEA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2027–2030)

TABLE 106 MEA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2017–2022)

TABLE 107 MEA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2023–2026)

TABLE 108 MEA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2027–2030)

TABLE 109 MEA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY COUNTRY, $M (2017–2022)

TABLE 110 MEA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY COUNTRY, $M (2023–2026)

TABLE 111 MEA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY COUNTRY, $M (2027–2030)

TABLE 112 U.S. MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2017–2022)

TABLE 113 U.S. MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2023–2026)

TABLE 114 U.S. MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2027–2030)

TABLE 115 U.S. MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2017–2022)

TABLE 116 U.S. MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2023–2026)

TABLE 117 U.S. MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2027–2030)

TABLE 118 U.S. HEMATOLOGICAL MALIGNANCIES TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 119 U.S. HEMATOLOGICAL MALIGNANCIES TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 120 U.S. HEMATOLOGICAL MALIGNANCIES TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 121 U.S. MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2017–2022)

TABLE 122 U.S. MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2023–2026)

TABLE 123 U.S. MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2027–2030)

TABLE 124 U.S. MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2017–2022)

TABLE 125 U.S. MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2023–2026)

TABLE 126 U.S. MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2027–2030)

TABLE 127 CANADA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2017–2022)

TABLE 128 CANADA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2023–2026)

TABLE 129 CANADA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2027–2030)

TABLE 130 CANADA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2017–2022)

TABLE 131 CANADA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2023–2026)

TABLE 132 CANADA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2027–2030)

TABLE 133 CANADA HEMATOLOGICAL MALIGNANCIES TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 134 CANADA HEMATOLOGICAL MALIGNANCIES TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 135 CANADA HEMATOLOGICAL MALIGNANCIES TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 136 CANADA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2017–2022)

TABLE 137 CANADA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2023–2026)

TABLE 138 CANADA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2027–2030)

TABLE 139 CANADA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2017–2022)

TABLE 140 CANADA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2023–2026)

TABLE 141 CANADA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2027–2030)

TABLE 142 GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2017–2022)

TABLE 143 GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2023–2026)

TABLE 144 GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2027–2030)

TABLE 145 GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2017–2022)

TABLE 146 GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2023–2026)

TABLE 147 GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2027–2030)

TABLE 148 GERMANY HEMATOLOGICAL MALIGNANCIES TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 149 GERMANY HEMATOLOGICAL MALIGNANCIES TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 150 GERMANY HEMATOLOGICAL MALIGNANCIES TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 151 GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2017–2022)

TABLE 152 GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2023–2026)

TABLE 153 GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2027–2030)

TABLE 154 GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2017–2022)

TABLE 155 GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2023–2026)

TABLE 156 GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2027–2030)

TABLE 157 FRANCE MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2017–2022)

TABLE 158 FRANCE MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2023–2026)

TABLE 159 FRANCE MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2027–2030)

TABLE 160 FRANCE MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2017–2022)

TABLE 161 FRANCE MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2023–2026)

TABLE 162 FRANCE MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2027–2030)

TABLE 163 FRANCE HEMATOLOGICAL MALIGNANCIES TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 164 FRANCE HEMATOLOGICAL MALIGNANCIES TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 165 FRANCE HEMATOLOGICAL MALIGNANCIES TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 166 FRANCE MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2017–2022)

TABLE 167 FRANCE MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2023–2026)

TABLE 168 FRANCE MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2027–2030)

TABLE 169 FRANCE MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2017–2022)

TABLE 170 FRANCE MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2023–2026)

TABLE 171 FRANCE MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2027–2030)

TABLE 172 U.K. MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2017–2022)

TABLE 173 U.K. MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2023–2026)

TABLE 174 U.K. MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2027–2030)

TABLE 175 U.K. MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2017–2022)

TABLE 176 U.K. MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2023–2026)

TABLE 177 U.K. MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2027–2030)

TABLE 178 U.K. HEMATOLOGICAL MALIGNANCIES TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 179 U.K. HEMATOLOGICAL MALIGNANCIES TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 180 U.K. HEMATOLOGICAL MALIGNANCIES TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 181 U.K. MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2017–2022)

TABLE 182 U.K. MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2023–2026)

TABLE 183 U.K. MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2027–2030)

TABLE 184 U.K. MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2017–2022)

TABLE 185 U.K. MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2023–2026)

TABLE 186 U.K. MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2027–2030)

TABLE 187 ITALY MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2017–2022)

TABLE 188 ITALY MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2023–2026)

TABLE 189 ITALY MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2027–2030)

TABLE 190 ITALY MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2017–2022)

TABLE 191 ITALY MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2023–2026)

TABLE 192 ITALY MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2027–2030)

TABLE 193 ITALY HEMATOLOGICAL MALIGNANCIES TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 194 ITALY HEMATOLOGICAL MALIGNANCIES TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 195 ITALY HEMATOLOGICAL MALIGNANCIES TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 196 ITALY MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2017–2022)

TABLE 197 ITALY MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2023–2026)

TABLE 198 ITALY MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2027–2030)

TABLE 199 ITALY MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2017–2022)

TABLE 200 ITALY MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2023–2026)

TABLE 201 ITALY MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2027–2030)

TABLE 202 SPAIN MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2017–2022)

TABLE 203 SPAIN MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2023–2026)

TABLE 204 SPAIN MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2027–2030)

TABLE 205 SPAIN MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2017–2022)

TABLE 206 SPAIN MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2023–2026)

TABLE 207 SPAIN MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2027–2030)

TABLE 208 SPAIN HEMATOLOGICAL MALIGNANCIES TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 209 SPAIN HEMATOLOGICAL MALIGNANCIES TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 210 SPAIN HEMATOLOGICAL MALIGNANCIES TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 211 SPAIN MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2017–2022)

TABLE 212 SPAIN MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2023–2026)

TABLE 213 SPAIN MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2027–2030)

TABLE 214 SPAIN MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2017–2022)

TABLE 215 SPAIN MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2023–2026)

TABLE 216 SPAIN MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2027–2030)

TABLE 217 JAPAN MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2017–2022)

TABLE 218 JAPAN MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2023–2026)

TABLE 219 JAPAN MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2027–2030)

TABLE 220 JAPAN MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2017–2022)

TABLE 221 JAPAN MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2023–2026)

TABLE 222 JAPAN MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2027–2030)

TABLE 223 JAPAN HEMATOLOGICAL MALIGNANCIES TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 224 JAPAN HEMATOLOGICAL MALIGNANCIES TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 225 JAPAN HEMATOLOGICAL MALIGNANCIES TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 226 JAPAN MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2017–2022)

TABLE 227 JAPAN MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2023–2026)

TABLE 228 JAPAN MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2027–2030)

TABLE 229 JAPAN MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2017–2022)

TABLE 230 JAPAN MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2023–2026)

TABLE 231 JAPAN MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2027–2030)

TABLE 232 CHINA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2017–2022)

TABLE 233 CHINA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2023–2026)

TABLE 234 CHINA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2027–2030)

TABLE 235 CHINA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2017–2022)

TABLE 236 CHINA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2023–2026)

TABLE 237 CHINA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2027–2030)

TABLE 238 CHINA HEMATOLOGICAL MALIGNANCIES TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 239 CHINA HEMATOLOGICAL MALIGNANCIES TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 240 CHINA HEMATOLOGICAL MALIGNANCIES TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 241 CHINA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2017–2022)

TABLE 242 CHINA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2023–2026)

TABLE 243 CHINA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2027–2030)

TABLE 244 CHINA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2017–2022)

TABLE 245 CHINA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2023–2026)

TABLE 246 CHINA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2027–2030)

TABLE 247 INDIA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2017–2022)

TABLE 248 INDIA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2023–2026)

TABLE 249 INDIA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2027–2030)

TABLE 250 INDIA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2017–2022)

TABLE 251 INDIA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2023–2026)

TABLE 252 INDIA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2027–2030)

TABLE 253 INDIA HEMATOLOGICAL MALIGNANCIES TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 254 INDIA HEMATOLOGICAL MALIGNANCIES TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 255 INDIA HEMATOLOGICAL MALIGNANCIES TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 256 INDIA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2017–2022)

TABLE 257 INDIA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2023–2026)

TABLE 258 INDIA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2027–2030)

TABLE 259 INDIA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2017–2022)

TABLE 260 INDIA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2023–2026)

TABLE 261 INDIA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2027–2030)

TABLE 262 AUSTRALIA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2017–2022)

TABLE 263 AUSTRALIA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2023–2026)

TABLE 264 AUSTRALIA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2027–2030)

TABLE 265 AUSTRALIA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2017–2022)

TABLE 266 AUSTRALIA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2023–2026)

TABLE 267 AUSTRALIA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2027–2030)

TABLE 268 AUSTRALIA HEMATOLOGICAL MALIGNANCIES TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 269 AUSTRALIA HEMATOLOGICAL MALIGNANCIES TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 270 AUSTRALIA HEMATOLOGICAL MALIGNANCIES TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 271 AUSTRALIA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2017–2022)

TABLE 272 AUSTRALIA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2023–2026)

TABLE 273 AUSTRALIA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2027–2030)

TABLE 274 AUSTRALIA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2017–2022)

TABLE 275 AUSTRALIA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2023–2026)

TABLE 276 AUSTRALIA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2027–2030)

TABLE 277 SOUTH KOREA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2017–2022)

TABLE 278 SOUTH KOREA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2023–2026)

TABLE 279 SOUTH KOREA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2027–2030)

TABLE 280 SOUTH KOREA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2017–2022)

TABLE 281 SOUTH KOREA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2023–2026)

TABLE 282 SOUTH KOREA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2027–2030)

TABLE 283 SOUTH KOREA HEMATOLOGICAL MALIGNANCIES TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 284 SOUTH KOREA HEMATOLOGICAL MALIGNANCIES TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 285 SOUTH KOREA HEMATOLOGICAL MALIGNANCIES TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 286 SOUTH KOREA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2017–2022)

TABLE 287 SOUTH KOREA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2023–2026)

TABLE 288 SOUTH KOREA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2027–2030)

TABLE 289 SOUTH KOREA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2017–2022)

TABLE 290 SOUTH KOREA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2023–2026)

TABLE 291 SOUTH KOREA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2027–2030)

TABLE 292 BRAZIL MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2017–2022)

TABLE 293 BRAZIL MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2023–2026)

TABLE 294 BRAZIL MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2027–2030)

TABLE 295 BRAZIL MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2017–2022)

TABLE 296 BRAZIL MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2023–2026)

TABLE 297 BRAZIL MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2027–2030)

TABLE 298 BRAZIL HEMATOLOGICAL MALIGNANCIES TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 299 BRAZIL HEMATOLOGICAL MALIGNANCIES TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 300 BRAZIL HEMATOLOGICAL MALIGNANCIES TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 301 BRAZIL MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2017–2022)

TABLE 302 BRAZIL MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2023–2026)

TABLE 303 BRAZIL MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2027–2030)

TABLE 304 BRAZIL MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2017–2022)

TABLE 305 BRAZIL MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2023–2026)

TABLE 306 BRAZIL MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2027–2030)

TABLE 307 MEXICO MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2017–2022)

TABLE 308 MEXICO MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2023–2026)

TABLE 309 MEXICO MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2027–2030)

TABLE 310 MEXICO MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2017–2022)

TABLE 311 MEXICO MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2023–2026)

TABLE 312 MEXICO MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2027–2030)

TABLE 313 MEXICO HEMATOLOGICAL MALIGNANCIES TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 314 MEXICO HEMATOLOGICAL MALIGNANCIES TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 315 MEXICO HEMATOLOGICAL MALIGNANCIES TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 316 MEXICO MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2017–2022)

TABLE 317 MEXICO MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2023–2026)

TABLE 318 MEXICO MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2027–2030)

TABLE 319 MEXICO MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2017–2022)

TABLE 320 MEXICO MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2023–2026)

TABLE 321 MEXICO MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2027–2030)

TABLE 322 SAUDI ARABIA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2017–2022)

TABLE 323 SAUDI ARABIA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2023–2026)

TABLE 324 SAUDI ARABIA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2027–2030)

TABLE 325 SAUDI ARABIA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2017–2022)

TABLE 326 SAUDI ARABIA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2023–2026)

TABLE 327 SAUDI ARABIA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2027–2030)

TABLE 328 SAUDI ARABIA HEMATOLOGICAL MALIGNANCIES TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 329 SAUDI ARABIA HEMATOLOGICAL MALIGNANCIES TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 330 SAUDI ARABIA HEMATOLOGICAL MALIGNANCIES TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 331 SAUDI ARABIA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2017–2022)

TABLE 332 SAUDI ARABIA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2023–2026)

TABLE 333 SAUDI ARABIA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2027–2030)

TABLE 334 SAUDI ARABIA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2017–2022)

TABLE 335 SAUDI ARABIA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2023–2026)

TABLE 336 SAUDI ARABIA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2027–2030)

TABLE 337 SOUTH AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2017–2022)

TABLE 338 SOUTH AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2023–2026)

TABLE 339 SOUTH AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2027–2030)

TABLE 340 SOUTH AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2017–2022)

TABLE 341 SOUTH AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2023–2026)

TABLE 342 SOUTH AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2027–2030)

TABLE 343 SOUTH AFRICA HEMATOLOGICAL MALIGNANCIES TESTING MARKET, BY TYPE, $M (2017–2022)

TABLE 344 SOUTH AFRICA HEMATOLOGICAL MALIGNANCIES TESTING MARKET, BY TYPE, $M (2023–2026)

TABLE 345 SOUTH AFRICA HEMATOLOGICAL MALIGNANCIES TESTING MARKET, BY TYPE, $M (2027–2030)

TABLE 346 SOUTH AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2017–2022)

TABLE 347 SOUTH AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2023–2026)

TABLE 348 SOUTH AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2027–2030)

TABLE 349 SOUTH AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2017–2022)

TABLE 350 SOUTH AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2023–2026)

TABLE 351 SOUTH AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2027–2030)

TABLE 352 ADAPTIVE BIOTECHNOLOGIES CORPORATION – AT A GLANCE

TABLE 353 ADAPTIVE BIOTECHNOLOGIES CORPORATION – KEY FINANCIAL SUMMARY

TABLE 354 F. HOFFMANN-LA ROCHE LTD. – AT A GLANCE

TABLE 355 F. HOFFMANN-LA ROCHE LTD. – KEY FINANCIAL SUMMARY

TABLE 356 CERGENTIS B.V. – AT A GLANCE

TABLE 357 BIO-RAD LABORATORIES INC. – AT A GLANCE

TABLE 358 BIO-RAD LABORATORIES INC. – KEY FINANCIAL SUMMARY

TABLE 359 ARUP LABORATORIES – AT A GLANCE

TABLE 360 ARUP LABORATORIES – KEY FINANCIAL SUMMARY

TABLE 361 LABORATORY CORPORATION OF AMERICA HOLDINGS – AT A GLANCE

TABLE 362 LABORATORY CORPORATION OF AMERICA HOLDINGS – KEY FINANCIAL SUMMARY

TABLE 363 GUARDANT HEALTH INC. – AT A GLANCE

TABLE 364 GUARDANT HEALTH INC. – KEY FINANCIAL SUMMARY

TABLE 365 SYSMEX CORPORATION – AT A GLANCE

TABLE 366 SYSMEX CORPORATION – KEY FINANCIAL SUMMARY

TABLE 367 MISSION BIO INC. – AT A GLANCE

TABLE 368 NATERA INC. – AT A GLANCE

TABLE 369 NATERA INC. – KEY FINANCIAL SUMMARY

TABLE 370 NEOGENOMICS LABORATORIES INC. – AT A GLANCE

TABLE 371 NEOGENOMICS LABORATORIES INC. – KEY FINANCIAL SUMMARY

TABLE 372 EXACT SCIENCES CORPORATION – AT A GLANCE

TABLE 373 EXACT SCIENCES CORPORATION – KEY FINANCIAL SUMMARY

TABLE 374 GRAIL LLC – AT A GLANCE

TABLE 375 VERACYTE INC. – AT A GLANCE

TABLE 376 VERACYTE INC. – KEY FINANCIAL SUMMARY

TABLE 377 FOUNDATION MEDICINE INC. – AT A GLANCE

TABLE 378 FOUNDATION MEDICINE INC. – KEY FINANCIAL SUMMARY

 

LIST OF FIGURES

FIG 1 MARKET SIZE BREAKDOWN BY SEGMENT

FIG 2 RESEARCH METHODOLOGY

FIG 3 BREAKDOWN OF PRIMARY RESEARCH, BY REGION

FIG 4 BREAKDOWN OF PRIMARY RESEARCH, BY DESIGNATION

FIG 5 BREAKDOWN OF PRIMARY RESEARCH, BY COMPANY TYPE

FIG 6 DATA TRIANGULATION APPROACH

FIG 7 CURRENCY CONVERSION RATES FOR USD (2023)

FIG 8 GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SUMMARY

FIG 9 BARGAINING POWER OF BUYERS

FIG 10 BARGAINING POWER OF SUPPLIERS

FIG 11 THREAT OF NEW ENTRANTS

FIG 12 INTENSITY OF RIVALRY

FIG 13 THREAT OF SUBSTITUTES

FIG 14 GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SNAPSHOT

FIG 15 GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2019–2030)

FIG 16 GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2019–2030)

FIG 17 GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2019–2030)

FIG 18 GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2019–2030)

FIG 19 MAJOR WORLDWIDE MARKETS FOR MINIMAL RESIDUAL DISEASE TESTING, $M

FIG 20 NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SNAPSHOT

FIG 21 NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2019–2030)

FIG 22 NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2019–2030)

FIG 23 NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2019–2030)

FIG 24 NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2019–2030)

FIG 25 NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY COUNTRY, $M (2019–2030)

FIG 26 EUROPE MINIMAL RESIDUAL DISEASE TESTING MARKET SNAPSHOT

FIG 27 EUROPE MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2019–2030)

FIG 28 EUROPE MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2019–2030)

FIG 29 EUROPE MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2019–2030)

FIG 30 EUROPE MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2019–2030)

FIG 31 EUROPE MINIMAL RESIDUAL DISEASE TESTING MARKET, BY COUNTRY, $M (2019–2030)

FIG 32 APAC MINIMAL RESIDUAL DISEASE TESTING MARKET SNAPSHOT

FIG 33 APAC MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2019–2030)

FIG 34 APAC MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2019–2030)

FIG 35 APAC MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2019–2030)

FIG 36 APAC MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2019–2030)

FIG 37 APAC MINIMAL RESIDUAL DISEASE TESTING MARKET, BY COUNTRY, $M (2019–2030)

FIG 38 LATAM MINIMAL RESIDUAL DISEASE TESTING MARKET SNAPSHOT

FIG 39 LATAM MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2019–2030)

FIG 40 LATAM MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2019–2030)

FIG 41 LATAM MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2019–2030)

FIG 42 LATAM MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2019–2030)

FIG 43 LATAM MINIMAL RESIDUAL DISEASE TESTING MARKET, BY COUNTRY, $M (2019–2030)

FIG 44 MEA MINIMAL RESIDUAL DISEASE TESTING MARKET SNAPSHOT

FIG 45 MEA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2019–2030)

FIG 46 MEA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2019–2030)

FIG 47 MEA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2019–2030)

FIG 48 MEA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2019–2030)

FIG 49 MEA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY COUNTRY, $M (2019–2030)

FIG 50 U.S. MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2019–2030)

FIG 51 U.S. MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2019–2030)

FIG 52 U.S. MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2019–2030)

FIG 53 U.S. MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2019–2030)

FIG 54 CANADA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2019–2030)

FIG 55 CANADA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2019–2030)

FIG 56 CANADA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2019–2030)

FIG 57 CANADA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2019–2030)

FIG 58 GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2019–2030)

FIG 59 GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2019–2030)

FIG 60 GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2019–2030)

FIG 61 GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2019–2030)

FIG 62 FRANCE MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2019–2030)

FIG 63 FRANCE MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2019–2030)

FIG 64 FRANCE MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2019–2030)

FIG 65 FRANCE MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2019–2030)

FIG 66 U.K. MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2019–2030)

FIG 67 U.K. MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2019–2030)

FIG 68 U.K. MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2019–2030)

FIG 69 U.K. MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2019–2030)

FIG 70 ITALY MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2019–2030)

FIG 71 ITALY MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2019–2030)

FIG 72 ITALY MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2019–2030)

FIG 73 ITALY MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2019–2030)

FIG 74 SPAIN MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2019–2030)

FIG 75 SPAIN MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2019–2030)

FIG 76 SPAIN MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2019–2030)

FIG 77 SPAIN MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2019–2030)

FIG 78 JAPAN MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2019–2030)

FIG 79 JAPAN MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2019–2030)

FIG 80 JAPAN MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2019–2030)

FIG 81 JAPAN MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2019–2030)

FIG 82 CHINA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2019–2030)

FIG 83 CHINA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2019–2030)

FIG 84 CHINA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2019–2030)

FIG 85 CHINA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2019–2030)

FIG 86 INDIA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2019–2030)

FIG 87 INDIA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2019–2030)

FIG 88 INDIA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2019–2030)

FIG 89 INDIA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2019–2030)

FIG 90 AUSTRALIA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2019–2030)

FIG 91 AUSTRALIA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2019–2030)

FIG 92 AUSTRALIA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2019–2030)

FIG 93 AUSTRALIA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2019–2030)

FIG 94 SOUTH KOREA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2019–2030)

FIG 95 SOUTH KOREA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2019–2030)

FIG 96 SOUTH KOREA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2019–2030)

FIG 97 SOUTH KOREA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2019–2030)

FIG 98 BRAZIL MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2019–2030)

FIG 99 BRAZIL MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2019–2030)

FIG 100 BRAZIL MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2019–2030)

FIG 101 BRAZIL MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2019–2030)

FIG 102 MEXICO MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2019–2030)

FIG 103 MEXICO MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2019–2030)

FIG 104 MEXICO MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2019–2030)

FIG 105 MEXICO MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2019–2030)

FIG 106 SAUDI ARABIA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2019–2030)

FIG 107 SAUDI ARABIA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2019–2030)

FIG 108 SAUDI ARABIA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2019–2030)

FIG 109 SAUDI ARABIA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2019–2030)

FIG 110 SOUTH AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2019–2030)

FIG 111 SOUTH AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2019–2030)

FIG 112 SOUTH AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2019–2030)

FIG 113 SOUTH AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2019–2030)

FIG 114 U.A.E. MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TEST TYPE, $M (2019–2030)

FIG 115 U.A.E. MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, $M (2019–2030)

FIG 116 U.A.E. MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, $M (2019–2030)

FIG 117 U.A.E. MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, $M (2019–2030)

FIG 118 ADAPTIVE BIOTECHNOLOGIES CORPORATION – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 119 F. HOFFMANN-LA ROCHE LTD. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 120 BIO-RAD LABORATORIES INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 121 ARUP LABORATORIES – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 122 LABORATORY CORPORATION OF AMERICA HOLDINGS – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 123 GUARDANT HEALTH INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 124 SYSMEX CORPORATION – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 125 NATERA INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 126 NEOGENOMICS LABORATORIES INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 127 EXACT SCIENCES CORPORATION – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 128 VERACYTE INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)

FIG 129 FOUNDATION MEDICINE INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2023)